

# Rafael Franco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8401759/publications.pdf>

Version: 2024-02-01

404  
papers

22,566  
citations

5896

81  
h-index

14208

128  
g-index

425  
all docs

425  
docs citations

425  
times ranked

17584  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plant-derived compounds, vitagens, vitagenes and mitochondrial function. <i>PharmaNutrition</i> , 2022, 19, 100287.	1.7	2
2	Expression of the Adenosine A2A-A3 Receptor Heteromer in Different Brain Regions and Marked Upregulation in the Microglia of the Transgenic APPSw,Ind Alzheimerâ€™s Disease Model. <i>Biomedicines</i> , 2022, 10, 214.	3.2	5
3	The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB2 Receptors. <i>Frontiers in Pharmacology</i> , 2022, 13, 852631.	3.5	2
4	Genetic Inactivation of Free Fatty Acid Receptor 3 Impedes Behavioral Deficits and Pathological Hallmarks in the APPsw Alzheimerâ€™s Disease Mouse Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3533.	4.1	3
5	Robustness of the Krebs Cycle under Physiological Conditions and in Cancer: New Clues for Evaluating Metabolism-Modifying Drug Therapies. <i>Biomedicines</i> , 2022, 10, 1199.	3.2	2
6	The Heteromeric Complex Formed by Dopamine Receptor D5 and CCR9 Leads the Gut Homing of CD4+ T Cells Upon Inflammation. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 489-506.	4.5	12
7	Dopamine in Health and Disease: Much More Than a Neurotransmitter. <i>Biomedicines</i> , 2021, 9, 109.	3.2	78
8	Geoffrey Burnstock (1929â€“2020): the finest pharmacologist and an inspiring scientist. <i>Purinergic Signalling</i> , 2021, 17, 135-135.	2.2	2
9	Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. <i>Clinical Science</i> , 2021, 135, 465-481.	4.3	45
10	Structure and function of adenosine receptor heteromers. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 3957-3968.	5.4	30
11	Discovery of a macromolecular complex mediating the hunger suppressive actions of cocaine: Structural and functional properties. <i>Addiction Biology</i> , 2021, 26, e13017.	2.6	6
12	Carnitine palmitoyltransferase 1C negatively regulates the endocannabinoid hydrolase ABHD6 in mice, depending on nutritional status. <i>British Journal of Pharmacology</i> , 2021, 178, 1507-1523.	5.4	11
13	Cuprizone-Induced Neurotoxicity in Human Neural Cell Lines Is Mediated by a Reversible Mitochondrial Dysfunction: Relevance for Demyelination Models. <i>Brain Sciences</i> , 2021, 11, 272.	2.3	9
14	Methamphetamine Blocks Adenosine A2A Receptor Activation via Sigma 1 and Cannabinoid CB1 Receptors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2743.	4.1	3
15	Genes Implicated in Familial Parkinsonâ€™s Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4643.	4.1	12
16	5-Hydroxytryptamine, Glutamate, and ATP: Much More Than Neurotransmitters. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 667815.	3.7	3
17	Interactions between ibuprofen, ACE2, reninâ€“angiotensin system, and spike protein in the lung. Implications for COVIDâ€“19. <i>Clinical and Translational Medicine</i> , 2021, 11, e371.	4.0	25
18	Microglial Adenosine Receptors: From Preconditioning to Modulating the M1/M2 Balance in Activated Cells. <i>Cells</i> , 2021, 10, 1124.	4.1	22

#	ARTICLE	IF	CITATIONS
19	Potent and Subtype-Selective Dopamine D <sub>2</sub> Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8710-8726.	6.4	3
20	Current Issues in Molecular Biology Journal Enters a New Era. <i>Current Issues in Molecular Biology</i> , 2021, 43, 384-388.	2.4	0
21	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB <sub>2</sub> Receptor Derived from the Natural Product Cannabidiol. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9354-9364.	6.4	27
22	Antioxidant Supplements versus Health Benefits of Brief/Intermittent Exposure to Potentially Toxic Physical or Chemical Agents. <i>Current Issues in Molecular Biology</i> , 2021, 43, 650-664.	2.4	7
23	Identification of the Ghrelin and Cannabinoid CB <sub>2</sub> Receptor Heteromer Functionality and Marked Upregulation in Striatal Neurons from Offspring of Mice under a High-Fat Diet. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8928.	4.1	4
24	An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria. <i>Redox Biology</i> , 2021, 46, 102078.	9.0	19
25	Novel Interactions Involving the Mas Receptor Show Potential of the Renin-Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia. <i>Neurotherapeutics</i> , 2021, 18, 998-1016.	4.4	11
26	Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1264, 81-92.	1.6	23
27	Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy. <i>Cells</i> , 2021, 10, 2831.	4.1	22
28	Similarities and differences upon binding of naturally occurring $\delta^9$ -tetrahydrocannabinol-derivatives to cannabinoid CB <sub>1</sub> and CB <sub>2</sub> receptors. <i>Pharmacological Research</i> , 2021, 174, 105970.	7.1	17
29	N-Methyl-D-aspartate (NMDA) and cannabinoid CB <sub>2</sub> receptors form functional complexes in cells of the central nervous system: insights into the therapeutic potential of neuronal and microglial NMDA receptors. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 184.	6.2	14
30	Ghrelin and Cannabinoid Functional Interactions Mediated by Ghrelin/CB <sub>1</sub> Receptor Heteromers That Are Upregulated in the Striatum From Offspring of Mice Under a High-Fat Diet. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 786597.	3.7	2
31	Melatonin and the control of intraocular pressure. <i>Progress in Retinal and Eye Research</i> , 2020, 75, 100798.	15.5	31
32	Adreno-melatonin receptor complexes control ion homeostasis and intraocular pressure - their disruption contributes to hypertensive glaucoma. <i>British Journal of Pharmacology</i> , 2020, 177, 2090-2105.	5.4	8
33	Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 256-271.	4.1	53
34	Structure of G-protein-coupled receptor heteromers. , 2020, , 109-119.		1
35	A <sub>2A</sub> and A <sub>2B</sub> adenosine receptors: The extracellular loop 2 determines high (A <sub>2A</sub> ) or low affinity (A <sub>2B</sub> ) for adenosine. <i>Biochemical Pharmacology</i> , 2020, 172, 113718.	4.4	24
36	Expression of GPR55 and either cannabinoid CB <sub>1</sub> or CB <sub>2</sub> heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates. <i>Brain Structure and Function</i> , 2020, 225, 2153-2164.	2.3	12

#	ARTICLE	IF	CITATIONS
37	SARS-CoV-2 as a Factor to Disbalance the Renin–Angiotensin System: A Suspect in the Case of Exacerbated IL-6 Production. <i>Journal of Immunology</i> , 2020, 205, 1198-1206.	0.8	18
38	Adenosine A2A and A3 Receptors Are Able to Interact with Each Other. A Further Piece in the Puzzle of Adenosine Receptor-Mediated Signaling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5070.	4.1	14
39	Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB <sub>2</sub> Receptor**. <i>Chemistry - A European Journal</i> , 2020, 26, 15839-15842.	3.3	20
40	Experimental and computational analysis of biased agonism on full-length and a C-terminally truncated adenosine A2A receptor. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 2723-2732.	4.1	20
41	Natural Compounds as Guides for the Discovery of Drugs Targeting G-Protein-Coupled Receptors. <i>Molecules</i> , 2020, 25, 5060.	3.8	8
42	Angiotensin AT1 and AT2 receptor heteromer expression in the hemilesioned rat model of Parkinson's disease that increases with levodopa-induced dyskinesia. <i>Journal of Neuroinflammation</i> , 2020, 17, 243.	7.2	16
43	Functional Complexes of Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Receptors: Expression in Adult but Not Fetal Lung Tissue. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9602.	4.1	11
44	Adenosine A2A Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer's Disease. <i>Cells</i> , 2020, 9, 1075.	4.1	36
45	Pharmacological potential of varinic-, minor-, and acidic phytocannabinoids. <i>Pharmacological Research</i> , 2020, 158, 104801.	7.1	30
46	Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors. <i>Pharmacological Research</i> , 2020, 159, 104940.	7.1	57
47	Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 12.	3.4	5
48	Expression of cannabinoid CB1 GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum. <i>Annals of the New York Academy of Sciences</i> , 2020, 1475, 34-42.	3.8	4
49	Adenosine/A2B Receptor Signaling Ameliorates the Effects of Aging and Counteracts Obesity. <i>Cell Metabolism</i> , 2020, 32, 56-70.e7.	16.2	77
50	DIMERBOW: exploring possible GPCR dimer interfaces. <i>Bioinformatics</i> , 2020, 36, 3271-3272.	4.1	7
51	Expression of Melatonin and Dopamine D3 Receptor Heteromers in Eye Ciliary Body Epithelial Cells and Negative Correlation with Ocular Hypertension. <i>Cells</i> , 2020, 9, 152.	4.1	12
52	The Old and New Visions of Biased Agonism Through the Prism of Adenosine Receptor Signaling and Receptor/Receptor and Receptor/Protein Interactions. <i>Frontiers in Pharmacology</i> , 2020, 11, 628601.	3.5	10
53	The Kinetic Component in Drug Discovery: Using the Most Basic Pharmacological Concepts to Advance in Selecting Drugs to Combat CNS Diseases. <i>Current Neuropharmacology</i> , 2020, 18, 250-257.	2.9	2
54	Cocaine Blocks Effects of Hunger Hormone, Ghrelin, Via Interaction with Neuronal Sigma-1 Receptors. <i>Molecular Neurobiology</i> , 2019, 56, 1196-1210.	4.0	13

#	ARTICLE	IF	CITATIONS
55	Potiation of cannabinoid signaling in microglia by adenosine A2A receptor antagonists. <i>Glia</i> , 2019, 67, 2410-2423.	4.9	36
56	Lessons on Differential Neuronal-Death-Vulnerability from Familial Cases of Parkinson's and Alzheimer's Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3297.	4.1	6
57	Editorial: Epigenetics in Mammalian Tissues. <i>Frontiers in Genetics</i> , 2019, 10, 635.	2.3	1
58	Antioxidants versus Food Antioxidant Additives and Food Preservatives. <i>Antioxidants</i> , 2019, 8, 542.	5.1	48
59	Hormetic and Mitochondria-Related Mechanisms of Antioxidant Action of Phytochemicals. <i>Antioxidants</i> , 2019, 8, 373.	5.1	48
60	Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson's Disease. <i>Molecular Neurobiology</i> , 2019, 56, 5900-5910.	4.0	22
61	Increased expression of cannabinoid CB2 and serotonin 5-HT1A heteroreceptor complexes in a model of newborn hypoxic-ischemic brain damage. <i>Neuropharmacology</i> , 2019, 152, 58-66.	4.1	25
62	Why have transgenic rodent models failed to successfully mimic Alzheimer's disease. How can we develop effective drugs without them?. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 327-330.	5.0	8
63	Antioxidant Defense Mechanisms in Erythrocytes and in the Central Nervous System. <i>Antioxidants</i> , 2019, 8, 46.	5.1	48
64	A2A Receptor Homodimer-Disrupting Sequence Efficiently Delivered by a Protease-Resistant, Cyclic CPP Vector. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4937.	4.1	9
65	Differential effect of amphetamine over the corticotropin-releasing factor CRF2 receptor, the orexin OX1 receptor and the CRF2-OX1 heteroreceptor complex. <i>Neuropharmacology</i> , 2019, 152, 102-111.	4.1	11
66	The sigma-1 receptor as key common factor in cocaine and food-seeking behaviors. <i>Journal of Molecular Endocrinology</i> , 2019, 63, R81-R92.	2.5	9
67	Specificity and nanomolar potency of melatonin on G-protein coupled melatonin MT1 and MT2 receptors expressed in HEK-293T human embryo kidney cells. <i>Melatonin Research</i> , 2019, 2, 121-131.	1.1	3
68	Identification of Heteroreceptors Complexes and Signal Transduction Events Using Bioluminescence Resonance Energy Transfer (BRET). <i>Bio-protocol</i> , 2019, 9, e3385.	0.4	1
69	Maternal imprinting on cognition markers of wild type and transgenic Alzheimer's disease model mice. <i>Scientific Reports</i> , 2018, 8, 6434.	3.3	15
70	Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims. <i>Neurotherapeutics</i> , 2018, 15, 796-806.	4.4	44
71	Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 173-179.	1.4	23
72	Orexin A/Hypocretin Modulates Leptin Receptor-Mediated Signaling by Allosteric Modulations Mediated by the Ghrelin GHS-R1A Receptor in Hypothalamic Neurons. <i>Molecular Neurobiology</i> , 2018, 55, 4718-4730.	4.0	14

#	ARTICLE	IF	CITATIONS
73	Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia. <i>Brain, Behavior, and Immunity</i> , 2018, 67, 139-151.	4.1	99
74	Adenosine A2A receptor ligand recognition and signaling is blocked by A2B receptors. <i>Oncotarget</i> , 2018, 9, 13593-13611.	1.8	77
75	Biased receptor functionality versus biased agonism in G-protein-coupled receptors. <i>Biomolecular Concepts</i> , 2018, 9, 143-154.	2.2	32
76	Identification of a Tool Compound to Study the Mechanisms of Functional Selectivity between D <sub>2</sub> and D <sub>3</sub> Dopamine Receptors. <i>ACS Omega</i> , 2018, 3, 17368-17375.	3.5	1
77	N-Methyl-D-Aspartate Receptor Link to the MAP Kinase Pathway in Cortical and Hippocampal Neurons and Microglia Is Dependent on Calcium Sensors and Is Blocked by $\beta$ -Synuclein, Tau, and Phospho-Tau in Non-transgenic and Transgenic APPSw,Ind Mice. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 273.	2.9	19
78	Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes. <i>Biochemical Pharmacology</i> , 2018, 157, 148-158.	4.4	74
79	Resveratrol and Related Stilbenoids, Nutraceutical/Dietary Complements with Health-Promoting Actions: Industrial Production, Safety, and the Search for Mode of Action. <i>Comprehensive Reviews in Food Science and Food Safety</i> , 2018, 17, 808-826.	11.7	38
80	Adenosine Receptors as a Paradigm to Identify Dimer/Oligomers of G-Protein-Coupled Receptors and as Targets in Parkinson's Disease and Schizophrenia. , 2018, , 239-258.		0
81	Analysis and Quantification of GPCR Allosteric Receptor-Receptor Interactions Using Radioligand Binding Assays: The A2AR-D2R Heteroreceptor Complex Example. <i>NeuroMethods</i> , 2018, , 1-14.	0.3	0
82	Methods to Identify the Signature of Trimers Formed by Three G Protein-Coupled Receptors or by Two G Protein-Coupled and One Ionotropic Receptor with Special Emphasis in the Functional Role in the Central Nervous System. <i>NeuroMethods</i> , 2018, , 187-203.	0.3	1
83	Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes. <i>Frontiers in Pharmacology</i> , 2018, 9, 632.	3.5	88
84	Adenosine A2A Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges. <i>Frontiers in Psychiatry</i> , 2018, 9, 68.	2.6	46
85	Brain Dopamine Transmission in Health and Parkinson's Disease: Modulation of Synaptic Transmission and Plasticity Through Volume Transmission and Dopamine Heteroreceptors. <i>Frontiers in Synaptic Neuroscience</i> , 2018, 10, 20.	2.5	43
86	Neuronal Calcium and cAMP Cross-Talk Mediated by Cannabinoid CB1 Receptor and EF-Hand Calcium Sensor Interactions. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 67.	3.7	13
87	Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes. <i>Frontiers in Neuroanatomy</i> , 2018, 12, 52.	1.7	19
88	Understanding the Role of Adenosine A2AR Heteroreceptor Complexes in Neurodegeneration and Neuroinflammation. <i>Frontiers in Neuroscience</i> , 2018, 12, 43.	2.8	44
89	Cocaine Effects on Dopaminergic Transmission Depend on a Balance between Sigma-1 and Sigma-2 Receptor Expression. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 17.	2.9	17
90	Cross-communication between Gi and Gs in a G-protein-coupled receptor heterotetramer guided by a receptor C-terminal domain. <i>BMC Biology</i> , 2018, 16, 24.	3.8	70

#	ARTICLE	IF	CITATIONS
91	Molecular and functional interaction between GPR18 and cannabinoid CB2 G-protein-coupled receptors. Relevance in neurodegenerative diseases. <i>Biochemical Pharmacology</i> , 2018, 157, 169-179.	4.4	47
92	Detection, Analysis, and Quantification of GPCR Homo- and Heteroreceptor Complexes in Specific Neuronal Cell Populations Using the In Situ Proximity Ligation Assay. <i>Neuromethods</i> , 2018, , 299-315.	0.3	3
93	Heteroreceptor Complexes Formed by Dopamine D1, Histamine H3, and N-Methyl-D-Aspartate Glutamate Receptors as Targets to Prevent Neuronal Death in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2017, 54, 4537-4550.	4.0	44
94	Health benefits of methylxanthines in neurodegenerative diseases. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1600670.	3.3	65
95	Potential of GPCRs to modulate MAPK and mTOR pathways in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2017, 149-150, 21-38.	5.7	42
96	Chemical rules on the assessment of antioxidant potential in food and food additives aimed at reducing oxidative stress and neurodegeneration. <i>Food Chemistry</i> , 2017, 235, 318-323.	8.2	30
97	Heteroreceptor Complexes Implicated in Parkinson's Disease. , 2017, , 477-501.		1
98	GPR55: A therapeutic target for Parkinson's disease?. <i>Neuropharmacology</i> , 2017, 125, 319-332.	4.1	67
99	Neurochemical evidence supporting dopamine D1/D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation. <i>Brain Structure and Function</i> , 2017, 222, 1767-1784.	2.3	58
100	A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice. <i>Neuropsychopharmacology</i> , 2017, 42, 524-539.	5.4	86
101	Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease. <i>Neuropharmacology</i> , 2017, 113, 110-123.	4.1	49
102	Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors. <i>Frontiers in Pharmacology</i> , 2017, 8, 744.	3.5	134
103	Humans and Caffeine: A Very Long Relationship. <i>Frontiers for Young Minds</i> , 2017, 5, .	0.8	0
104	Epigenetics in the Eye: An Overview of the Most Relevant Ocular Diseases. <i>Frontiers in Genetics</i> , 2017, 8, 144.	2.3	28
105	The Epigenetic Cytocrin Pathway to the Nucleus. Epigenetic Factors, Epigenetic Mediators, and Epigenetic Traits. A Biochemist Perspective. <i>Frontiers in Genetics</i> , 2017, 8, 179.	2.3	10
106	A genomics approach identifies selective effects of trans-resveratrol in cerebral cortex neuron and glia gene expression. <i>PLoS ONE</i> , 2017, 12, e0176067.	2.5	9
107	Understanding the Functional Plasticity in Neural Networks of the Basal Ganglia in Cocaine Use Disorder: A Role for Allosteric Receptor-Receptor Interactions in A2A-D2 Heteroreceptor Complexes. <i>Neural Plasticity</i> , 2016, 2016, 1-12.	2.2	28
108	Targeting Cannabinoid CB2 Receptors in the Central Nervous System. <i>Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders. Frontiers in Neuroscience</i> , 2016, 10, 406.	2.8	108

#	ARTICLE	IF	CITATIONS
109	Basic Pharmacological and Structural Evidence for Class A G-Protein-Coupled Receptor Heteromerization. <i>Frontiers in Pharmacology</i> , 2016, 7, 76.	3.5	98
110	Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid $\langle \text{scp} \rangle \langle \text{cGMP} \rangle \langle \text{scp} \rangle$ levels. <i>Journal of Neurochemistry</i> , 2016, 136, 403-415.	3.9	41
111	Two Affinity Sites of the Cannabinoid Subtype 2 Receptor Identified by a Novel Homogeneous Binding Assay. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 580-587.	2.5	20
112	Disruption of a dopamine receptor complex amplifies the actions of cocaine. <i>European Neuropsychopharmacology</i> , 2016, 26, 1366-1377.	0.7	36
113	Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration. <i>Cell Death and Disease</i> , 2016, 7, e2427-e2427.	6.3	87
114	Quaternary structure of a G-protein-coupled receptor heterotetramer in complex with Gi and Gs. <i>BMC Biology</i> , 2016, 14, 26.	3.8	97
115	Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2016, 57, 94-105.	4.1	51
116	Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6753-6771.	6.4	34
117	Presynaptic P2X1-3 and $\beta$ 3-containing nicotinic receptors assemble into functionally interacting ion channels in the rat hippocampus. <i>Neuropharmacology</i> , 2016, 105, 241-257.	4.1	14
118	Increased expression with differential subcellular location of cytidine deaminase APOBEC3G in human CD4 + T cell activation and dendritic cell maturation. <i>Immunology and Cell Biology</i> , 2016, 94, 689-700.	2.3	9
119	The potential of methylxanthine-based therapies in pediatric respiratory tract diseases. <i>Respiratory Medicine</i> , 2016, 112, 1-9.	2.9	45
120	Hints on the Lateralization of Dopamine Binding to D1 Receptors in Rat Striatum. <i>Molecular Neurobiology</i> , 2016, 53, 5436-5445.	4.0	7
121	Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1. <i>Journal of Leukocyte Biology</i> , 2016, 99, 349-359.	3.3	20
122	Purinergic signaling in Parkinson's disease. Relevance for treatment. <i>Neuropharmacology</i> , 2016, 104, 161-168.	4.1	68
123	Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors. <i>Molecular Neurobiology</i> , 2016, 53, 2312-2319.	4.0	32
124	Structures for G-Protein-Coupled Receptor Tetramers in Complex with G Proteins. <i>Trends in Biochemical Sciences</i> , 2015, 40, 548-551.	7.5	60
125	Suggesting a Way to Understand the Actual Potential of Anti-Alzheimer's Disease Drugs That Show Promise in Transgenic Mouse Models. <i>Frontiers in Neurology</i> , 2015, 6, 206.	2.4	1
126	Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum. <i>Biochemical Pharmacology</i> , 2015, 96, 131-142.	4.4	59



#	ARTICLE	IF	CITATIONS
127	Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease. <i>Clinical Epigenetics</i> , 2015, 7, 108.	4.1	52
128	Decreased levels of guanosine 3',5'-cyclic monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 471-482.	3.2	84
129	Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. <i>Brain Structure and Function</i> , 2015, 220, 2721-2738.	2.3	82
130	The relevance of theobromine for the beneficial effects of cocoa consumption. <i>Frontiers in Pharmacology</i> , 2015, 6, 30.	3.5	100
131	Alternatively activated microglia and macrophages in the central nervous system. <i>Progress in Neurobiology</i> , 2015, 131, 65-86.	5.7	561
132	Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia. <i>Molecular Neurobiology</i> , 2015, 52, 1408-1420.	4.0	49
133	Enhancing cognition before clinical symptoms of dementia. <i>Frontiers in Systems Neuroscience</i> , 2014, 8, 240.	2.5	1
134	CCR5/CD4/CXCR4 oligomerization prevents HIV-1 gp120 binding to the cell surface. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1960-9.	7.1	45
135	Successful therapies for Alzheimer's disease: why so many in animal models and none in humans?. <i>Frontiers in Pharmacology</i> , 2014, 5, 146.	3.5	138
136	Potential of caveolae in the therapy of cardiovascular and neurological diseases. <i>Frontiers in Physiology</i> , 2014, 5, 370.	2.8	17
137	GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells. <i>Hippocampus</i> , 2014, 24, 733-739.	1.9	46
138	Conversaciones entre el sistema nervioso y el sistema inmunológico. <i>Revista Internacional De Acupuntura</i> , 2014, 8, 147-148.	0.1	0
139	G-Protein-Coupled Receptor Heteromers as Key Players in the Molecular Architecture of the Central Nervous System. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 703-709.	3.9	23
140	Neuroprotective Potential of Adenosine A <sub>2A</sub> and Cannabinoid CB <sub>1</sub> Receptor Antagonists in an Animal Model of Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2014, 73, 414-424.	1.7	31
141	Understanding the Added Value of G-Protein-Coupled Receptor Heteromers. <i>Scientifica</i> , 2014, 2014, 1-7.	1.7	6
142	Heteromerization of GPR55 and cannabinoid CB <sub>2</sub> receptors modulates signalling. <i>British Journal of Pharmacology</i> , 2014, 171, 5387-5406.	5.4	105
143	L-DOPA-treatment in primates disrupts the expression of A <sub>2A</sub> adenosine CB <sub>1</sub> cannabinoid D <sub>2</sub> dopamine receptor heteromers in the caudate nucleus. <i>Neuropharmacology</i> , 2014, 79, 90-100.	4.1	83
144	CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. <i>Experimental Neurology</i> , 2014, 261, 44-52.	4.1	73

#	ARTICLE	IF	CITATIONS
145	Phosphodiesterase Inhibition in Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S561-S573.	2.6	24
146	Synthesis and Evaluation of <sup>13</sup> N-Labelled Azo Compounds for $\beta$ -Amyloid Imaging in Mice. <i>Molecular Imaging and Biology</i> , 2014, 16, 538-549.	2.6	14
147	Dopamine receptor heteromeric complexes and their emerging functions. <i>Progress in Brain Research</i> , 2014, 211, 183-200.	1.4	38
148	l-DOPA disrupts adenosine A <sub>2A</sub> -cannabinoid CB <sub>1</sub> -dopamine D <sub>2</sub> receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies. <i>Experimental Neurology</i> , 2014, 253, 180-191.	4.1	77
149	The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. <i>Neurobiology of Aging</i> , 2014, 35, 2603-2616.	3.1	71
150	Differential Neuroprotective Effects of 5'-Deoxy-5'-Methylthioadenosine. <i>PLoS ONE</i> , 2014, 9, e90671.	2.5	13
151	Challenges in the Development of Heteromer-GPCR-Based Drugs. <i>Progress in Molecular Biology and Translational Science</i> , 2013, 117, 143-162.	1.7	10
152	A <sub>1R</sub> -A <sub>2AR</sub> heteromers coupled to G <sub>s</sub> and G <sub>i/o</sub> proteins modulate GABA transport into astrocytes. <i>Purinergic Signalling</i> , 2013, 9, 433-449.	2.2	123
153	Epigenetic drugs in Alzheimer's disease. <i>Biomolecular Concepts</i> , 2013, 4, 433-445.	2.2	30
154	CB <sub>2</sub> receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. <i>Neurobiology of Aging</i> , 2013, 34, 805-808.	3.1	152
155	The catalytic site structural gate of adenosine deaminase allosterically modulates ligand binding to adenosine receptors. <i>FASEB Journal</i> , 2013, 27, 1048-1061.	0.5	35
156	Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT <sub>1A</sub> and CB <sub>2</sub> receptors. <i>Neuropharmacology</i> , 2013, 71, 282-291.	4.1	182
157	Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. <i>Neuropharmacology</i> , 2013, 64, 114-123.	4.1	143
158	Health Benefits of Methylxanthines in Cacao and Chocolate. <i>Nutrients</i> , 2013, 5, 4159-4173.	4.1	155
159	Detection of Receptor Heteromers Involving Dopamine Receptors by the Sequential BRET-FRET Technology. <i>Methods in Molecular Biology</i> , 2013, 964, 95-105.	0.9	10
160	Cocaine Inhibits Dopamine D <sub>2</sub> Receptor Signaling via Sigma-1-D <sub>2</sub> Receptor Heteromers. <i>PLoS ONE</i> , 2013, 8, e61245.	2.5	112
161	Phenyl Acyl Acids Attenuate the Unfolded Protein Response in Tunicamycin-Treated Neuroblastoma Cells. <i>PLoS ONE</i> , 2013, 8, e71082.	2.5	12
162	Phenylbutyrate is a Multifaceted Drug that Exerts Neuroprotective Effects and Reverses the Alzheimer's Disease-like Phenotype of a Commonly Used Mouse Model. <i>Current Pharmaceutical Design</i> , 2013, 19, 5076-5084.	1.9	59

#	ARTICLE	IF	CITATIONS
163	Age-Related Mitochondrial Alterations without Neuronal Loss in the Hippocampus of a Transgenic Model of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2013, 10, 390-405.	1.4	27
164	Circadian-Related Heteromerization of Adrenergic and Dopamine D4 Receptors Modulates Melatonin Synthesis and Release in the Pineal Gland. <i>PLoS Biology</i> , 2012, 10, e1001347.	5.6	132
165	Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain. <i>Journal of Biological Chemistry</i> , 2012, 287, 20851-20865.	3.4	196
166	Loss of Parvalbumin-Positive Neurons From the Globus Pallidus in Animal Models of Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 973-982.	1.7	16
167	Chronic Mild Stress Accelerates the Onset and Progression of the Alzheimer's Disease Phenotype in Tg2576 Mice. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 567-578.	2.6	54
168	Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2012, 3, 832-844.	3.5	216
169	An old enzyme for current needs: adenosine deaminase and a dendritic cell vaccine for HIV. <i>Immunology and Cell Biology</i> , 2012, 90, 594-600.	2.3	7
170	Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain. <i>Molecular Psychiatry</i> , 2012, 17, 650-662.	7.9	82
171	Transcriptional profiling of striatal neurons in response to single or concurrent activation of dopamine D2, adenosine A2A and metabotropic glutamate type 5 receptors: Focus on beta-synuclein expression. <i>Gene</i> , 2012, 508, 199-205.	2.2	5
172	Unmasking adenosine 2A receptors (A2ARs) in monkey basal ganglia output neurons using cholera toxin subunit B (CTB). <i>Neurobiology of Disease</i> , 2012, 47, 347-357.	4.4	4
173	Adenosine Deaminase Enhances the Immunogenicity of Human Dendritic Cells from Healthy and HIV-Infected Individuals. <i>PLoS ONE</i> , 2012, 7, e51287.	2.5	21
174	Dopamine-Galanin Receptor Heteromers Modulate Cholinergic Neurotransmission in the Rat Ventral Hippocampus. <i>Journal of Neuroscience</i> , 2011, 31, 7412-7423.	3.6	31
175	Biotin Ergopeptide Probes for Dopamine Receptors. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1080-1090.	6.4	13
176	Modulation of GABA Transport by Adenosine A1R-A2AR Heteromers, Which Are Coupled to Both Gs- and Gi/o-Proteins. <i>Journal of Neuroscience</i> , 2011, 31, 15629-15639.	3.6	16
177	Chronic mild stress in mice promotes cognitive impairment and CDK5-dependent tau hyperphosphorylation. <i>Behavioural Brain Research</i> , 2011, 220, 338-343.	2.2	37
178	Real-Time G-Protein-Coupled Receptor Imaging to Understand and Quantify Receptor Dynamics. <i>Scientific World Journal</i> , The, 2011, 11, 1995-2010.	2.1	2
179	A2A adenosine receptor ligand binding and signalling is allosterically modulated by adenosine deaminase. <i>Biochemical Journal</i> , 2011, 435, 701-709.	3.7	37
180	Adenosine A2A Receptors and A2A Receptor Heteromers as Key Players in Striatal Function. <i>Frontiers in Neuroanatomy</i> , 2011, 5, 36.	1.7	44

#	ARTICLE	IF	CITATIONS
181	Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist. <i>Addiction Biology</i> , 2011, 16, 405-415.	2.6	50
182	Sildenafil restores cognitive function without affecting $\beta$ 2-amyloid burden in a mouse model of Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2011, 164, 2029-2041.	5.4	159
183	Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease. , 2011, 132, 280-299.		170
184	Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of <i>Macaca fascicularis</i> . <i>Journal of Psychopharmacology</i> , 2011, 25, 97-104.	4.0	120
185	Abnormal calcium handling in atrial fibrillation is linked to up-regulation of adenosine A2A receptors. <i>European Heart Journal</i> , 2011, 32, 721-729.	2.2	67
186	Dopamine D1-histamine H3 Receptor Heteromers Provide a Selective Link to MAPK Signaling in GABAergic Neurons of the Direct Striatal Pathway. <i>Journal of Biological Chemistry</i> , 2011, 286, 5846-5854.	3.4	109
187	Striatal Pre- and Postsynaptic Profile of Adenosine A2A Receptor Antagonists. <i>PLoS ONE</i> , 2011, 6, e16088.	2.5	115
188	Cocaine self-administration markedly increases dopamine D <sub>2</sub> receptor negative cooperativity for dopamine binding: A receptor dimer-based analysis. <i>Synapse</i> , 2010, 64, 566-569.	1.2	8
189	Adenosine-cannabinoid receptor interactions. Implications for striatal function. <i>British Journal of Pharmacology</i> , 2010, 160, 443-453.	5.4	113
190	G <sub>i</sub> protein coupling to adenosine A <sub>1</sub> -A <sub>2A</sub> receptor heteromers in human brain caudate nucleus. <i>Journal of Neurochemistry</i> , 2010, 114, 972-980.	3.9	14
191	A Hybrid Indoloquinolizidine Peptide as Allosteric Modulator of Dopamine D1 Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 876-885.	2.5	13
192	Direct involvement of $\beta$ -1 receptors in the dopamine D <sub>1</sub> receptor-mediated effects of cocaine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18676-18681.	7.1	153
193	Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. <i>Journal of Leukocyte Biology</i> , 2010, 88, 279-290.	3.3	192
194	Interactions between Intracellular Domains as Key Determinants of the Quaternary Structure and Function of Receptor Heteromers. <i>Journal of Biological Chemistry</i> , 2010, 285, 27346-27359.	3.4	102
195	Prime Time for G-Protein-Coupled Receptor Heteromers as Therapeutic Targets for CNS disorders: The Dopamine D1-D3 Receptor Heteromer. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 596-600.	1.4	23
196	Platforms for the identification of GPCR targets, and of orthosteric and allosteric modulators. <i>Expert Opinion on Drug Discovery</i> , 2010, 5, 391-403.	5.0	6
197	Oligomerization of G-protein-coupled receptors: A reality. <i>Current Opinion in Pharmacology</i> , 2010, 10, 1-5.	3.5	60
198	Calcium-mediated modulation of the quaternary structure and function of adenosine A2A-dopamine D2 receptor heteromers. <i>Current Opinion in Pharmacology</i> , 2010, 10, 67-72.	3.5	25

#	ARTICLE	IF	CITATIONS
199	Cocaine produces D2R-mediated conformational changes in the adenosine A2AR-dopamine D2R heteromer. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 988-992.	2.1	25
200	G Protein-Coupled Receptor Heteromers as New Targets for Drug Development. <i>Progress in Molecular Biology and Translational Science</i> , 2010, 91, 41-52.	1.7	46
201	Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells. <i>Journal of Leukocyte Biology</i> , 2010, 89, 127-136.	3.3	59
202	Increased Î±-Defensins 1-3 Production by Dendritic Cells in HIV-Infected Individuals Is Associated with Slower Disease Progression. <i>PLoS ONE</i> , 2010, 5, e9436.	2.5	40
203	Interactions between Calmodulin, Adenosine A2A, and Dopamine D2 Receptors. <i>Journal of Biological Chemistry</i> , 2009, 284, 28058-28068.	3.4	65
204	Dynamic Regulation of CXCR1 and CXCR2 Homo- and Heterodimers. <i>Journal of Immunology</i> , 2009, 183, 7337-7346.	0.8	44
205	GPCR homomers and heteromers: A better choice as targets for drug development than GPCR monomers?. , 2009, 124, 248-257.		84
206	Useful pharmacological parameters for G-protein-coupled receptor homodimers obtained from competition experiments. Agonist-antagonist binding modulation. <i>Biochemical Pharmacology</i> , 2009, 78, 1456-1463.	4.4	39
207	Indoloquinolizidine-Peptide Hybrids as Multiple Agonists for D <sub>1</sub> and D <sub>2</sub> Dopamine Receptors. <i>ChemMedChem</i> , 2009, 4, 1514-1522.	3.2	16
208	Neurotransmitter receptor heteromers in neurodegenerative diseases and neural plasticity. <i>Journal of Neural Transmission</i> , 2009, 116, 983-987.	2.8	12
209	Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. <i>Psychopharmacology</i> , 2009, 206, 313-324.	3.1	108
210	Immunological dysfunction in HIV-1 infected individuals caused by impairment of adenosine deaminase-induced costimulation of T cell activation. <i>Immunology</i> , 2009, 128, 393-404.	4.4	25
211	Adenosine deaminase enhances T cell response elicited by dendritic cells loaded with inactivated HIV. <i>Immunology and Cell Biology</i> , 2009, 87, 634-639.	2.3	26
212	Building a new conceptual framework for receptor heteromers. <i>Nature Chemical Biology</i> , 2009, 5, 131-134.	8.0	349
213	Marked changes in signal transduction upon heteromerization of dopamine D <sub>1</sub> and histamine H <sub>3</sub> receptors. <i>British Journal of Pharmacology</i> , 2009, 157, 64-75.	5.4	138
214	G-protein-coupled receptor heteromers or how neurons can display differently flavoured patterns in response to the same neurotransmitter. <i>British Journal of Pharmacology</i> , 2009, 158, 23-31.	5.4	23
215	Metabotropic glutamate type 5, dopamine D <sub>2</sub> and adenosine A <sub>2a</sub> receptors form higher-order oligomers in living cells. <i>Journal of Neurochemistry</i> , 2009, 109, 1497-1507.	3.9	249
216	The association of metabotropic glutamate receptor type 5 with the neuronal Ca <sup>2+</sup> -binding protein 2 modulates receptor function. <i>Journal of Neurochemistry</i> , 2009, 111, 555-567.	3.9	27

#	ARTICLE	IF	CITATIONS
217	Looking for the role of cannabinoid receptor heteromers in striatal function. <i>Neuropharmacology</i> , 2009, 56, 226-234.	4.1	82
218	Adenosine A <sub>2A</sub> Receptor-Antagonist/Dopamine D <sub>2</sub> Receptor-Agonist Bivalent Ligands as Pharmacological Tools to Detect A <sub>2A</sub> -D <sub>2</sub> Receptor Heteromers. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5590-5602.	6.4	129
219	Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. <i>Haematologica</i> , 2009, 94, 1771-1775.	3.5	63
220	Light resonance energy transfer-based methods in the study of G protein-coupled receptor oligomerization. <i>BioEssays</i> , 2008, 30, 82-89.	2.5	37
221	G-protein-coupled receptor heteromers: function and ligand pharmacology. <i>British Journal of Pharmacology</i> , 2008, 153, S90-8.	5.4	60
222	Detection of heteromerization of more than two proteins by sequential BRET-FRET. <i>Nature Methods</i> , 2008, 5, 727-733.	19.0	269
223	Human adenosine deaminase as an allosteric modulator of human A <sub>1</sub> adenosine receptor: abolishment of negative cooperativity for [ <sup>3</sup> H](R)- $\epsilon$ binding to the caudate nucleus. <i>Journal of Neurochemistry</i> , 2008, 107, 161-170.	3.9	45
224	Detection of higher-order G protein-coupled receptor oligomers by a combined BRET-BiFC technique. <i>FEBS Letters</i> , 2008, 582, 2979-2984.	2.8	89
225	Plasma membrane diffusion of g protein-coupled receptor oligomers. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2008, 1783, 2262-2268.	4.1	41
226	Novel pharmacological targets based on receptor heteromers. <i>Brain Research Reviews</i> , 2008, 58, 475-482.	9.0	32
227	Response to Drs. Straub and Jessop. <i>Trends in Immunology</i> , 2008, 29, 304-305.	6.8	0
228	Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. <i>Neuropharmacology</i> , 2008, 54, 815-823.	4.1	154
229	Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. <i>Neuropharmacology</i> , 2008, 55, 190-197.	4.1	157
230	How Calmodulin Interacts with the Adenosine A <sub>2A</sub> and the Dopamine D <sub>2</sub> Receptors. <i>Journal of Proteome Research</i> , 2008, 7, 3428-3434.	3.7	42
231	Identification of Dopamine D1-D3 Receptor Heteromers. <i>Journal of Biological Chemistry</i> , 2008, 283, 26016-26025.	3.4	216
232	An Update on Adenosine A <sub>2A</sub> -Dopamine D <sub>2</sub> Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors. <i>Current Pharmaceutical Design</i> , 2008, 14, 1468-1474.	1.9	229
233	Detection of Heteromers Formed by Cannabinoid CB <sub>1</sub> , Dopamine D <sub>2</sub> , and Adenosine A <sub>2A</sub> -G-Protein-Coupled Receptors by Combining Bimolecular Fluorescence Complementation and Bioluminescence Energy Transfer. <i>Scientific World Journal</i> , The, 2008, 8, 1088-1097.	2.1	105
234	Adenosine A <sub>1</sub> -A <sub>2A</sub> receptor heteromers: new targets for caffeine in the brain. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 2391.	3.0	135

#	ARTICLE	IF	CITATIONS
235	Actin-binding Protein $\beta$ -Actinin-1 Interacts with the Metabotropic Glutamate Receptor Type 5b and Modulates the Cell Surface Expression and Function of the Receptor. <i>Journal of Biological Chemistry</i> , 2007, 282, 12143-12153.	3.4	37
236	Heteromeric Nicotinic Acetylcholineâ€“Dopamine Autoreceptor Complexes Modulate Striatal Dopamine Release. <i>Neuropsychopharmacology</i> , 2007, 32, 35-42.	5.4	63
237	Reply: Does the adenosine A2A receptor stimulate the ryanodine receptor?. <i>Cardiovascular Research</i> , 2007, 73, 249-250.	3.8	2
238	Functional relevance of neurotransmitter receptor heteromers in the central nervous system. <i>Trends in Neurosciences</i> , 2007, 30, 440-446.	8.6	136
239	Adenosine receptorâ€“dopamine receptor interactions in the basal ganglia and their relevance for brain function. <i>Physiology and Behavior</i> , 2007, 92, 210-217.	2.1	239
240	Aspects of the general biology of adenosine A2A signaling. <i>Progress in Neurobiology</i> , 2007, 83, 263-276.	5.7	168
241	Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain. <i>Neurobiology of Learning and Memory</i> , 2007, 87, 42-56.	1.9	115
242	The neuronal Ca <sup>2+</sup> -binding protein 2 (NECAB2) interacts with the adenosine A2A receptor and modulates the cell surface expression and function of the receptor. <i>Molecular and Cellular Neurosciences</i> , 2007, 36, 1-12.	2.2	37
243	The emergence of neurotransmitters as immune modulators. <i>Trends in Immunology</i> , 2007, 28, 400-407.	6.8	112
244	Novel Ergopeptides as Dual Ligands for Adenosine and Dopamine Receptors. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3062-3069.	6.4	39
245	Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes that Mediate the Motor Effects of Cannabinoids. <i>Neuropsychopharmacology</i> , 2007, 32, 2249-2259.	5.4	229
246	Adenosine Receptor Heteromers and their Integrative Role in Striatal Function. <i>Scientific World Journal, The</i> , 2007, 7, 74-85.	2.1	89
247	Basic Concepts in G-Protein-Coupled Receptor Homo- and Heterodimerization. <i>Scientific World Journal, The</i> , 2007, 7, 48-57.	2.1	83
248	Enzymatic and Extraenzymatic Role of Adenosine Deaminase 1 in T-Cell-Dendritic Cell Contacts and in Alterations of the Immune Function. <i>Critical Reviews in Immunology</i> , 2007, 27, 495-509.	0.5	53
249	Neurologic Improvement in a Type 3 Gaucher Disease Patient Treated with Imiglucerase/Miglustat Combination. <i>Epilepsia</i> , 2007, 48, 1406-1408.	5.1	59
250	Increase in A2A receptors in the nucleus accumbens after extended cocaine self-administration and its disappearance after cocaine withdrawal. <i>Brain Research</i> , 2007, 1143, 208-220.	2.2	52
251	Neurotransmitter receptor heteromers and their integrative role in â€“local modulesâ€™: The striatal spine module. <i>Brain Research Reviews</i> , 2007, 55, 55-67.	9.0	112
252	Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monomeric and dimeric receptors: The receptorâ€“dimer cooperativity index. , 2007, 116, 343-354.		70

#	ARTICLE	IF	CITATIONS
253	Role of glutamate on T-cell mediated immunity. <i>Journal of Neuroimmunology</i> , 2007, 185, 9-19.	2.3	148
254	A $\beta$ peptides as one of the crucial volume transmission signals in the trophic units and their interactions with homocysteine. Physiological implications and relevance for Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2007, 114, 21-31.	2.8	36
255	Receptor-receptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins. <i>Journal of Neural Transmission</i> , 2007, 114, 93-104.	2.8	69
256	Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. <i>Journal of Neural Transmission</i> , 2007, 114, 49-75.	2.8	113
257	Adenosine A2A-cannabinoid CB1 receptor heteromers. Implications for the rewarding effects of cannabinoids. <i>FASEB Journal</i> , 2007, 21, A410.	0.5	0
258	Allosteric Modulation of Dopamine D2 Receptors by Homocysteine. <i>Journal of Proteome Research</i> , 2006, 5, 3077-3083.	3.7	53
259	Heterodimeric adenosine receptors: a device to regulate neurotransmitter release. <i>Cellular and Molecular Life Sciences</i> , 2006, 63, 2427-2431.	5.4	88
260	Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. <i>Brain Research</i> , 2006, 1077, 67-80.	2.2	90
261	Adenosine A2A receptors are expressed in human atrial myocytes and modulate spontaneous sarcoplasmic reticulum calcium release. <i>Cardiovascular Research</i> , 2006, 72, 292-302.	3.8	62
262	The Two-State Dimer Receptor Model: A General Model for Receptor Dimers. <i>Molecular Pharmacology</i> , 2006, 69, 1905-1912.	2.3	76
263	Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1-A2A Receptor Heteromers. <i>Journal of Neuroscience</i> , 2006, 26, 2080-2087.	3.6	553
264	Glutamate Released by Dendritic Cells as a Novel Modulator of T Cell Activation. <i>Journal of Immunology</i> , 2006, 177, 6695-6704.	0.8	130
265	Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease. <i>Haematologica</i> , 2006, 91, 703-6.	3.5	37
266	Trafficking of Adenosine A <sub>2A</sub> and Dopamine D <sub>2</sub> Receptors. <i>Journal of Molecular Neuroscience</i> , 2005, 25, 191-200.	2.3	42
267	Role of Electrostatic Interaction in Receptor-Receptor Heteromerization. <i>Journal of Molecular Neuroscience</i> , 2005, 26, 125-132.	2.3	74
268	Adenosine A <sub>2A</sub> and Dopamine D <sub>2</sub> Heteromeric Receptor Complexes and Their Function. <i>Journal of Molecular Neuroscience</i> , 2005, 26, 209-220.	2.3	207
269	Partners for Adenosine A <sub>1</sub> Receptors. <i>Journal of Molecular Neuroscience</i> , 2005, 26, 221-232.	2.3	25
270	Heptaspanning Membrane Receptors and Cytoskeletal/Scaffolding Proteins: Focus on Adenosine, Dopamine, and Metabotropic Glutamate Receptor Function. <i>Journal of Molecular Neuroscience</i> , 2005, 26, 277-292.	2.3	25



#	ARTICLE	IF	CITATIONS
271	Existence and Theoretical Aspects of Homomeric and Heteromeric Dopamine Receptor Complexes and Their Relevance for Neurological Diseases. <i>NeuroMolecular Medicine</i> , 2005, 7, 061-078.	3.4	21
272	Molecular mechanisms involved in the adenosine A1 and A2A receptor-induced neuronal differentiation in neuroblastoma cells and striatal primary cultures. <i>Journal of Neurochemistry</i> , 2005, 92, 337-348.	3.9	56
273	Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. <i>Journal of Neurochemistry</i> , 2005, 95, 919-929.	3.9	140
274	Dimer-based model for heptaspanning membrane receptors. <i>Trends in Biochemical Sciences</i> , 2005, 30, 360-366.	7.5	60
275	Studies on homocysteine plasma levels in Alzheimer's patients. Relevance for neurodegeneration. <i>Journal of Neural Transmission</i> , 2005, 112, 163-169.	2.8	44
276	CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 9583-9588.	7.1	229
277	ROLE OF ADENOSINE IN THE CONTROL OF HOMOSYNAPTIC PLASTICITY IN STRIATAL EXCITATORY SYNAPSES. <i>Journal of Integrative Neuroscience</i> , 2005, 04, 445-464.	1.7	45
278	Adenosine A2A Receptor and Dopamine D3 Receptor Interactions: Evidence of Functional A2A/D3 Heteromeric Complexes. <i>Molecular Pharmacology</i> , 2005, 67, 400-407.	2.3	119
279	New Methods to Evaluate Colocalization of Fluorophores in Immunocytochemical Preparations as Exemplified by a Study on A2A and D2 Receptors in Chinese Hamster Ovary Cells. <i>Journal of Histochemistry and Cytochemistry</i> , 2005, 53, 941-953.	2.5	43
280	On the Nested Hierarchical Organization of CNS: Basic Characteristics of Neuronal Molecular Networks. <i>Lecture Notes in Computer Science</i> , 2004, , 24-54.	1.3	21
281	ATP-Sensitive K <sup>+</sup> Channels Regulate the Concentrative Adenosine Transporter CNT2 following Activation by A <sub>1</sub> Adenosine Receptors. <i>Molecular and Cellular Biology</i> , 2004, 24, 2710-2719.	2.3	51
282	Group I Metabotropic Glutamate Receptors Mediate a Dual Role of Glutamate in T Cell Activation. <i>Journal of Biological Chemistry</i> , 2004, 279, 33352-33358.	3.4	113
283	Up-regulation of the Kv3.4 potassium channel subunit in early stages of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2004, 91, 547-557.	3.9	78
284	Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-d-aspartate receptor stimulation. <i>Journal of Neurochemistry</i> , 2004, 91, 873-880.	3.9	107
285	On the Molecular Basis of the Receptor Mosaic Hypothesis of the Engram. <i>Cellular and Molecular Neurobiology</i> , 2004, 24, 501-516.	3.3	30
286	Combining Mass Spectrometry and Pull-Down Techniques for the Study of Receptor Heteromerization. Direct Epitope-Epitope Electrostatic Interactions between Adenosine A2A and Dopamine D2 Receptors. <i>Analytical Chemistry</i> , 2004, 76, 5354-5363.	6.5	195
287	Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. <i>Brain Research Bulletin</i> , 2004, 64, 155-164.	3.0	32
288	Adenosine A2A-dopamine D2 receptor receptor heteromers. Targets for neuro-psychiatric disorders. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 265-271.	2.2	132

#	ARTICLE	IF	CITATIONS
289	Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 273-280.	2.2	72
290	Mutual regulation between metabotropic glutamate type 1 receptor and caveolin proteins: from traffick to constitutive activity. <i>Experimental Cell Research</i> , 2004, 300, 23-34.	2.6	26
291	Regulation of heptaspanning-membrane-receptor function by dimerization and clustering. <i>Trends in Biochemical Sciences</i> , 2003, 28, 238-243.	7.5	74
292	Metabotropic glutamate type 1 receptor localizes in low-density caveolin-rich plasma membrane fractions. <i>Journal of Neurochemistry</i> , 2003, 86, 785-791.	3.9	31
293	Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. <i>Journal of Neurochemistry</i> , 2003, 88, 726-734.	3.9	139
294	Ligand-induced caveolae-mediated internalization of A1 adenosine receptors: morphological evidence of endosomal sorting and receptor recycling. <i>Experimental Cell Research</i> , 2003, 285, 72-90.	2.6	65
295	Adenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization. <i>Journal of Biological Chemistry</i> , 2003, 278, 46741-46749.	3.4	401
296	Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons. <i>Pharmacological Reviews</i> , 2003, 55, 509-550.	16.0	306
297	The Adenosine A2A Receptor Interacts with the Actin-binding Protein $\beta$ -Actinin. <i>Journal of Biological Chemistry</i> , 2003, 278, 37545-37552.	3.4	100
298	A Role for Interleukin-12 in the Regulation of T Cell Plasma Membrane Compartmentation. <i>Journal of Biological Chemistry</i> , 2003, 278, 24849-24857.	3.4	32
299	Glutamate mGlu5-Adenosine A2A-Dopamine D2 Receptor Interactions in the Striatum. Implications for Drug Therapy in Neuro-psychiatric Disorders and Drug Abuse. <i>Current Medicinal Chemistry - Central Nervous System Agents</i> , 2003, 3, 1-26.	0.5	18
300	Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer's Disease and Mediate Both Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation. <i>Brain Pathology</i> , 2003, 13, 440-451.	4.1	150
301	Coaggregation, Cointernalization, and Codesensitization of Adenosine A2A Receptors and Dopamine D2Receptors. <i>Journal of Biological Chemistry</i> , 2002, 277, 18091-18097.	3.4	450
302	Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11940-11945.	7.1	345
303	Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction. <i>Biochemical Journal</i> , 2002, 361, 203.	3.7	34
304	Interactions among adenosine deaminase, adenosine A1 receptors and dopamine D1 receptors in stably cotransfected fibroblast cells and neurons. <i>Neuroscience</i> , 2002, 113, 709-719.	2.3	55
305	Adenosine A1 Receptor in Cultured Neurons from Rat Cerebral Cortex. <i>Journal of Neurochemistry</i> , 2002, 75, 656-664.	3.9	43
306	Modulation of GH4 Cell Cycle via A1 Adenosine Receptors. <i>Journal of Neurochemistry</i> , 2002, 69, 2145-2154.	3.9	8

#	ARTICLE	IF	CITATIONS
307	Regulation of L-Type Calcium Channels in GH4 Cells via A1 Adenosine Receptors. <i>Journal of Neurochemistry</i> , 2002, 69, 2546-2554.	3.9	19
308	Heteromerization of Adenosine and Dopamine Receptor Subtypes: Relevance for Neuronal Integration in Normal and Pathological States. <i>Advances in Behavioral Biology</i> , 2002, , 199-204.	0.2	2
309	Involvement of Caveolin in Ligand-Induced Recruitment and Internalization of A <sub>1</sub> Adenosine Receptor and Adenosine Deaminase in an Epithelial Cell Line. <i>Molecular Pharmacology</i> , 2001, 59, 1314-1323.	2.3	84
310	Adenosine/dopamine receptor-receptor interactions in the central nervous system. <i>Drug Development Research</i> , 2001, 52, 296-302.	2.9	11
311	Adenosine-glutamate receptor-receptor interactions in the central nervous system. <i>Drug Development Research</i> , 2001, 52, 316-322.	2.9	4
312	Metabotropic Glutamate 1 $\pm$ and Adenosine A1 Receptors Assemble into Functionally Interacting Complexes. <i>Journal of Biological Chemistry</i> , 2001, 276, 18345-18351.	3.4	170
313	Comodulation of CXCR4 and CD26 in Human Lymphocytes. <i>Journal of Biological Chemistry</i> , 2001, 276, 19532-19539.	3.4	89
314	Evidence for Adenosine/Dopamine Receptor Interactions Indications for Heteromerization. <i>Neuropsychopharmacology</i> , 2000, 23, S50-S59.	5.4	147
315	Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 8606-8611.	7.1	419
316	The Heat Shock Cognate Protein hsc73 Assembles with A 1 Adenosine Receptors To Form Functional Modules in the Cell Membrane. <i>Molecular and Cellular Biology</i> , 2000, 20, 5164-5174.	2.3	62
317	MECHANISMS OF CD26/DIPEPTIDYL PEPTIDASE IV CYTOKINE-DEPENDENT REGULATION ON HUMAN ACTIVATED LYMPHOCYTES. <i>Cytokine</i> , 2000, 12, 1136-1141.	3.2	42
318	The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression. <i>FEBS Letters</i> , 2000, 477, 123-128.	2.8	32
319	CD26 and Adenosine Deaminase Interaction: Its Role in the Fusion Between Horse Membrane Vesicles and Spermatozoa1. <i>Biology of Reproduction</i> , 1999, 61, 802-808.	2.7	41
320	Epidermal growth factor (EGF)-induced up-regulation and agonist- and antagonist-induced desensitization and internalization of A1 adenosine receptors in a pituitary-derived cell line. <i>Brain Research</i> , 1999, 816, 47-57.	2.2	29
321	Potential of ATP calcium responses by A2B receptor stimulation and other signals coupled to Gs proteins in type-1 cerebellar astrocytes. <i>Glia</i> , 1999, 26, 119-128.	4.9	69
322	Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. <i>Immunological Reviews</i> , 1998, 161, 27-42.	6.0	158
323	Ecto-adenosine deaminase: An ecto-enzyme and a costimulatory protein acting on a variety of cell surface receptors. , 1998, 45, 261-268.		12
324	Ecto-ADA in the development of the immune system. <i>Trends in Immunology</i> , 1998, 19, 533.	7.5	10

#	ARTICLE	IF	CITATIONS
325	Adenosine Deaminase and A1 Adenosine Receptors Internalize Together following Agonist-induced Receptor Desensitization. <i>Journal of Biological Chemistry</i> , 1998, 273, 17610-17617.	3.4	93
326	Ligand-Induced Phosphorylation, Clustering, and Desensitization of A <sub>1</sub> Adenosine Receptors. <i>Molecular Pharmacology</i> , 1997, 52, 788-797.	2.3	80
327	Cell surface adenosine deaminase: Much more than an ectoenzyme. <i>Progress in Neurobiology</i> , 1997, 52, 283-294.	5.7	224
328	Dipropylcyclopentylxanthine triggers apoptosis in Jurkat T cells by a receptor-independent mechanism. <i>Cell Death and Differentiation</i> , 1997, 4, 639-646.	11.2	3
329	Calcium mobilization in Jurkat cells via A2b adenosine receptors. <i>British Journal of Pharmacology</i> , 1997, 122, 1075-1082.	5.4	57
330	Ammonium toxicity in different cell lines. , 1997, 56, 530-537.		19
331	HIV-1 Envelope gp120 and Viral Particles Block Adenosine Deaminase Binding to Human CD26. <i>Advances in Experimental Medicine and Biology</i> , 1997, 421, 185-192.	1.6	7
332	The Cluster-Arranged Cooperative Model: A Model That Accounts for the Kinetics of Binding to A1 Adenosine Receptors. <i>Biochemistry</i> , 1996, 35, 3007-3015.	2.5	38
333	Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. <i>FEBS Letters</i> , 1996, 380, 219-223.	2.8	150
334	Adenosine Deaminase Interacts with A <sub>1</sub> Adenosine Receptors in Pig Brain Cortical Membranes. <i>Journal of Neurochemistry</i> , 1996, 66, 1675-1682.	3.9	58
335	Immunological identification of A1 adenosine receptors in brain cortex. <i>Journal of Neuroscience Research</i> , 1995, 42, 818-828.	2.9	121
336	A model of the pentose phosphate pathway in rat liver cells. <i>Molecular and Cellular Biochemistry</i> , 1995, 142, 9-17.	3.1	41
337	Surface adenosine deaminase. <i>Human Immunology</i> , 1995, 42, 265-273.	2.4	16
338	Characterization of the GTP/GDP binding site in the murine CD3- $\eta$ polypeptide chain. <i>Immunology Letters</i> , 1994, 43, 167-175.	2.5	3
339	A1 Adenosine receptors can occur manifesting two kinetic components of 8-cyclopentyl-1,3-[3H]dipropylxanthine ([3H]DPCPX) binding. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1994, 349, 485-491.	3.0	2
340	Solubilization and molecular characterization of the nitrobenzylthioinosine binding sites from pig kidney brush-border membranes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1994, 1191, 94-102.	2.6	9
341	Adenine nucleotides and adenosine metabolism in pig kidney proximal tubule membranes. <i>Journal of Cellular Physiology</i> , 1993, 157, 77-83.	4.1	12
342	The T cell receptor associated CD3- $\mu$ protein is phosphorylated upon T cell activation in the two tyrosine residues of a conserved signal transduction motif. <i>European Journal of Immunology</i> , 1993, 23, 1636-1642.	2.9	37

#	ARTICLE	IF	CITATIONS
343	Role of Histidine Residues in Agonist and Antagonist Binding Sites of A1 Adenosine Receptor. <i>Journal of Neurochemistry</i> , 1993, 60, 1525-1533.	3.9	10
344	Graphical analysis of data from pharmacology experiments. <i>Pharmacological Research</i> , 1992, 25, 325-334.	7.1	0
345	Characterization of adenosine receptors in brush border membranes from pig kidney. <i>British Journal of Pharmacology</i> , 1992, 107, 671-678.	5.4	23
346	The distribution of A1 adenosine receptor and 5'-nucleotidase in pig brain cortex subcellular fractions. <i>Neurochemical Research</i> , 1992, 17, 129-139.	3.3	10
347	The Adenosine Receptors Present on the Plasma Membrane of Chromaffin Cells Are of the A2b Subtype. <i>Journal of Neurochemistry</i> , 1992, 59, 425-431.	3.9	32
348	Modulation of adenosine agonist [ <sup>3</sup> H]N6-(R)-phenylisopropyladenosine binding to pig brain cortical membranes by changes of membrane fluidity and of medium physicochemical characteristics. <i>European Journal of Pharmacology</i> , 1992, 225, 7-14.	2.6	15
349	Theoretical study about the variability of the genome of foot-and-mouth disease viruses. <i>International Journal of Biochemistry &amp; Cell Biology</i> , 1992, 24, 325-329.	0.5	0
350	Interaction of trans-acting factors with the proximal promoter of the mouse $\beta$ -fetoprotein gene. <i>International Journal of Biochemistry &amp; Cell Biology</i> , 1992, 24, 1985-1989.	0.5	0
351	N-ethylmaleimide affects agonist binding to A1 adenosine receptors differently in the presence than in the absence of ligand. <i>Biochemical and Biophysical Research Communications</i> , 1991, 181, 213-218.	2.1	9
352	Application of Progress Curve Analysis to Enzyme Kinetic Studies Using Radioactive Measurements. <i>Analytical Letters</i> , 1991, 24, 1545-1552.	1.8	0
353	The binding of [ <sup>3</sup> H]R-PIA to A1 adenosine receptors produces a conversion of the high- to the low-affinity state. <i>FEBS Letters</i> , 1991, 286, 221-224.	2.8	14
354	New possibilities in the therapy of immunodeficiency diseases. <i>Immunology Letters</i> , 1991, 29, 277-279.	2.5	0
355	Adenosine Receptors in Myelin Fractions and Subfractions: The Effect of the Agonist (R)-Phenylisopropyladenosine on Myelin Membrane Microviscosity. <i>Journal of Neurochemistry</i> , 1991, 57, 1623-1629.	3.9	15
356	Effect of phospholipases and proteases on the [ <sup>3</sup> H]N6-(R)-phenylisopropyladenosine ([ <sup>3</sup> H]R-PIA) binding to A1 adenosine receptors from pig cerebral cortex. <i>Journal of Cellular Biochemistry</i> , 1991, 47, 278-288.	2.6	13
357	A new strategy for the evaluation of force parameters from quantum mechanical computations. <i>Journal of Computational Chemistry</i> , 1991, 12, 664-674.	3.3	39
358	Biochemical systems theory: Increasing predictive power by using second-order derivatives measurements. <i>Journal of Theoretical Biology</i> , 1991, 149, 521-535.	1.7	12
359	Control analysis of transition times. <i>Molecular and Cellular Biochemistry</i> , 1991, 101, 83-91.	3.1	11
360	Effect of Endogenous Phospholipids on the [ <sup>3</sup> H]R-Pia Binding to A <sub>1</sub> Adenosine Receptors from PIG Cerebral Cortex. <i>Nucleosides &amp; Nucleotides</i> , 1991, 10, 1141-1143.	0.5	3

#	ARTICLE	IF	CITATIONS
361	Release of adenosine deaminase from rat intestinal mucosa. <i>Biochemical Society Transactions</i> , 1990, 18, 641-642.	3.4	2
362	Distribution of A1-adenosine receptors, adenosine deaminase and 5â€²-nucleotidase in brain and other tissues of the pig. <i>Biochemical Society Transactions</i> , 1990, 18, 639-641.	3.4	2
363	Preparative purification of adenosine deaminase from human erythrocytes by affinity chromatography. <i>Biomedical Applications</i> , 1990, 532, 75-85.	1.7	8
364	A quantum chemical study of the enzymatic deamination of benzoadenine derivatives. A theoretical model of the interactions occurring between nucleosides and the active site of adenosine deaminase. <i>FEBS Journal</i> , 1990, 188, 155-163.	0.2	19
365	Control analysis of systems having two steps catalyzed by the same protein molecule in unbranched chains. <i>FEBS Journal</i> , 1990, 192, 369-371.	0.2	12
366	Quantum Chemical Study of the Electronic and Conformational Characteristics of Adenosine and 8-Substituted Derivatives: Functional Implications in the Mechanism of Reaction of Adenosine Deaminase. <i>Journal of Pharmaceutical Sciences</i> , 1990, 79, 133-137.	3.3	10
367	Solubilization of A1adenosine receptor from pig brain: Characterization and evidence of the role of the cell membrane on the coexistence of high- and low-affinity states. <i>Journal of Neuroscience Research</i> , 1990, 26, 461-473.	2.9	64
368	A method for binding parameters estimation of A1 adenosine receptor subtype: A practical approach. <i>Analytical Biochemistry</i> , 1990, 184, 117-123.	2.4	18
369	Theoretical study of the acidic strength of amino acid side chains. <i>Bioorganic Chemistry</i> , 1990, 18, 361-372.	4.1	2
370	Slight differences between adenosine deaminases from different species an immunochemical study. <i>Archives Internationales De Physiologie Et De Biochimie</i> , 1990, 98, 421-431.	0.2	0
371	Purification of Adenosine Deaminase from Chicken-Egg Yolk by Affinity Column Chromatography. <i>Preparative Biochemistry and Biotechnology</i> , 1990, 20, 199-204.	0.5	1
372	Theoretical study of the hydroxyl nucleophilic attack on the 6-aminopyrimidine molecule: functional implications in the reaction mechanism of nucleoside deaminative enzymes. <i>Journal of Organic Chemistry</i> , 1990, 55, 2630-2637.	3.2	15
373	Computer simulated process of "lead optimization": A student-interactive program. <i>Journal of Chemical Education</i> , 1990, 67, 232.	2.3	0
374	Ab initio study of the protonation and the tautomerism of the 7-aminopyrazolopyrimidine molecule. <i>Journal of Organic Chemistry</i> , 1990, 55, 753-756.	3.2	9
375	Determination of the conformational preferences of adenosine at the active site of adenosine deaminase. <i>Journal of the American Chemical Society</i> , 1990, 112, 8221-8229.	13.7	14
376	Is adenosine deaminase involved in adenosine transport?. <i>Medical Hypotheses</i> , 1990, 33, 245-250.	1.5	5
377	Further characterization of adenosine transport in renal brush-border membranes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1990, 1024, 241-248.	2.6	29
378	Practical Determination of Control Coefficients in Metabolic Pathways. , 1990, , 157-169.		2

#	ARTICLE	IF	CITATIONS
379	Performance Indices in Metabolic Systems: a Criterion for Evaluating Effectiveness in Metabolic Regulation. , 1990, , 149-156.		0
380	TEFOOL/2: a program for theoretical drug design on microcomputers. <i>Bioinformatics</i> , 1989, 5, 219-226.	4.1	0
381	Theoretical Approximation to the Reaction Mechanism of Adenosine Deaminase. <i>QSAR and Combinatorial Science</i> , 1989, 8, 109-114.	1.2	9
382	Interdependence between cooperativity and control coefficients. <i>BioSystems</i> , 1989, 23, 7-14.	2.0	4
383	Intuitive science. <i>Nature</i> , 1989, 338, 536-536.	27.8	0
384	Use of implicit methods from general sensitivity theory to develop a systematic approach to metabolic control. I. unbranched pathways. <i>Mathematical Biosciences</i> , 1989, 94, 271-288.	1.9	74
385	Use of implicit methods from general sensitivity theory to develop a systematic approach to metabolic control. II. complex systems. <i>Mathematical Biosciences</i> , 1989, 94, 289-309.	1.9	79
386	Heterogeneity of the gradients performed by the freeze-thaw method. <i>Journal of Proteomics</i> , 1989, 18, 177-182.	2.4	4
387	Identification and rejection of outliers in enzyme kinetics. <i>International Journal of Bio-medical Computing</i> , 1988, 23, 9-20.	0.5	23
388	Degradation of adenosine by extracellular adenosine deaminase in the rat duodenum. <i>General Pharmacology</i> , 1988, 19, 679-681.	0.7	15
389	Cytochemical demonstration of 5â€²-nucleotidase in rat brain synaptosomes. <i>Biochemical Society Transactions</i> , 1987, 15, 528-529.	3.4	0
390	Rapid purification of adenosine deaminase from rat liver. <i>Biochemical Society Transactions</i> , 1987, 15, 884-885.	3.4	1
391	Simulation of the purine nucleotide cycle as an anaplerotic process in skeletal muscle. <i>Archives of Biochemistry and Biophysics</i> , 1987, 254, 142-155.	3.0	14
392	Distribution of adenosine deaminase in some rat tissues. Inhibition by ethanol and dimethyl sulfoxide. <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1987, 86, 95-98.	0.2	4
393	A laboratory experiment on the purification of catalase. <i>Biochemical Education</i> , 1986, 14, 84-87.	0.1	4
394	Enzymes of the purine metabolism in rat brain microsomes. <i>Neurochemical Research</i> , 1986, 11, 407-422.	3.3	7
395	Heterogeneous localization of some purine enzymes in subcellular fractions of rat brain and cerebellum. <i>Neurochemical Research</i> , 1986, 11, 423-435.	3.3	65
396	Kinetics of the 5?-nucleotidase and the adenosine deaminase in subcellular fractions of rat brain. <i>Neurochemical Research</i> , 1986, 11, 471-479.	3.3	14

#	ARTICLE	IF	CITATIONS
397	An Improved Method for the Preparation of Rat Brain Microsomes. Biological Chemistry Hoppe-Seyler, 1986, 367, 307-312.	1.4	0
398	SIMCODE: A program for simulating point mutations in genomic DNA. Biochemical Education, 1985, 13, 66-67.	0.1	0
399	Computer-based learning of cooperativity and allostery. Bioinformatics, 1985, 1, 161-165.	4.1	0
400	Computer simulation of purine metabolism. FEBS Journal, 1984, 144, 305-315.	0.2	29
401	A program for the numerical integration of enzyme kinetic equations using small computers. International Journal of Bio-medical Computing, 1984, 15, 419-432.	0.5	15
402	Cholesterol in autism spectrum disorders. , 0, , .		0
403	Science plus technology to address challenges in determining the efficacy of neuroprotective/neurorestorative therapies. , 0, , .		1
404	Introductory and Basic aspects. , 0, , 1090-1103.		0